SOPHiA GENETICS (SOPH) to Release Earnings on Tuesday

SOPHiA GENETICS (NASDAQ:SOPH) is expected to be issuing its Q4 2025 results before the market opens on Tuesday, March 3rd. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $21.20 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 3, 2026 at 8:00 AM ET.

SOPHiA GENETICS Price Performance

NASDAQ SOPH opened at $4.50 on Friday. The stock has a 50-day simple moving average of $4.93 and a 200 day simple moving average of $4.41. SOPHiA GENETICS has a twelve month low of $2.58 and a twelve month high of $5.70. The stock has a market capitalization of $304.11 million, a PE ratio of -9.78 and a beta of 1.11. The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.62 and a current ratio of 2.80.

Analyst Ratings Changes

A number of brokerages have recently commented on SOPH. BTIG Research upped their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Guggenheim upped their target price on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, Wall Street Zen raised shares of SOPHiA GENETICS to a “hold” rating in a report on Saturday, November 1st. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, SOPHiA GENETICS presently has an average rating of “Hold” and a consensus target price of $7.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC bought a new stake in SOPHiA GENETICS in the 3rd quarter valued at $49,000. Quadrature Capital Ltd bought a new position in shares of SOPHiA GENETICS during the 4th quarter worth about $54,000. XTX Topco Ltd acquired a new stake in shares of SOPHiA GENETICS during the 4th quarter valued at about $55,000. Susquehanna International Group LLP bought a new stake in SOPHiA GENETICS in the third quarter valued at about $88,000. Finally, Polen Capital Management LLC acquired a new position in SOPHiA GENETICS in the fourth quarter worth about $102,000. 31.59% of the stock is owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.